Chen Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Chen Yu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Lei Li
Institute of Systems and Physical Biology, Shenzhen Bay Laboratory, Shenzhen, China
4 shared publications - Dong Gao
Key Laboratory of Multi-Cell Systems, Shanghai Key Laboratory of Molecular Andrology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
3 shared publications - Luonan Chen
School of Mathematical Sciences and School of AI, Shanghai Jiao Tong University, Shanghai, China
3 shared publications Wei Wang
Institute of Cancer Research, Shenzhen Bay Laboratory, Shenzhen, China
3 shared publicationsYunyi Peng
Key Laboratory of Multi-Cell Systems, Shanghai Key Laboratory of Molecular Andrology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China
3 shared publications- Dan Li
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9964
Alternative tandem transcription initiation links noncoding variants to human disease through translational control
Alternative tandem transcription initiation is a pervasive mechanism of gene regulation, yet its genetic impact on human disease remains largely unknown. Here, we systematically quantify the genetic regulation of alternative tandem transcription initiation across 25,859 samples from 49 normal human tissues and 33 tumor tissues. We identify approximately 0.4 million genetic variants associated with alternative transcription initiation in 5295 genes, with 32% operating independently of gene expression. Moreover, we discover 2238 multi-tissue alternative tandem transcription initiation outliers enriched for rare deleterious promoter and 5′ UTR variants, demonstrating that both common and rare variants modulate transcription initiation. Strikingly, 74% of disease variants that colocalize with genetic variants regulating alternative transcription initiation cannot be identified through expression quantitative trait loci. Transcriptome-wide association studies identify 614 disease susceptibility genes associated with alternative transcription initiation, including known cancer drivers such as MAFF and MLLT10. Functional validation uncovers OSGEP as a breast cancer risk gene, where the alternative allele lengthens the 5′ UTR and reduces protein abundance through upstream open reading frame-mediated translation repression, and suppresses breast cancer cell proliferation. Our findings establish alternative transcription initiation as a major, underappreciated mechanism associating noncoding variation with disease, providing a critical resource for interpreting disease risk loci.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9964
Open AccessAlternative tandem transcription initiation links noncoding variants to human disease through translational control
Alternative tandem transcription initiation is a pervasive mechanism of gene regulation, yet its genetic impact on human disease remains largely unknown. Here, we systematically quantify the genetic regulation of alternative tandem transcription initiation across 25,859 samples from 49 normal human tissues and 33 tumor tissues. We identify approximately 0.4 million genetic variants associated with alternative transcription initiation in 5295 genes, with 32% operating independently of gene expression. Moreover, we discover 2238 multi-tissue alternative tandem transcription initiation outliers enriched for rare deleterious promoter and 5′ UTR variants, demonstrating that both common and rare variants modulate transcription initiation. Strikingly, 74% of disease variants that colocalize with genetic variants regulating alternative transcription initiation cannot be identified through expression quantitative trait loci. Transcriptome-wide association studies identify 614 disease susceptibility genes associated with alternative transcription initiation, including known cancer drivers such as MAFF and MLLT10. Functional validation uncovers OSGEP as a breast cancer risk gene, where the alternative allele lengthens the 5′ UTR and reduces protein abundance through upstream open reading frame-mediated translation repression, and suppresses breast cancer cell proliferation. Our findings establish alternative transcription initiation as a major, underappreciated mechanism associating noncoding variation with disease, providing a critical resource for interpreting disease risk loci.
- Open Access
- 5 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (59) , e76910
Redirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy
During glioma progression, monocytes abundantly infiltrate but primarily differentiate into immunosuppressive macrophages to promote tumor growth. Redirecting monocyte differentiation offers a compelling yet underexplored therapeutic opportunity. In this work, we found M1‐polarized macrophage‐derived extracellular vesicles (M1‐EVs) efficiently induced monocytes to differentiate into anti‐tumor macrophages via tumor necrosis factor alpha (TNF‐α)‐mediated signaling. Despite promising, the therapeutic efficacy of M1‐EVs was constrained by insufficient glioma accumulation and CD47‐mediated phagocytic inhibition. To address this challenge, we further engineered M1‐EVs with dual‐targeting specificity by genetically incorporating a tumor‐directed chimeric antigen receptor (CAR) against IL13Rα2 or EGFRvIII together with CD47‐blocking SIRPα variants. The resulting dual‐targeting EVs (M1‐CS‐EVs) exhibited enhanced blood‐brain barrier (BBB) penetration and glioma accumulation while locally disrupting CD47‐SIRPα interactions. In three orthotopic glioma models, M1‐CS‐EVs elicited a potent anti‐tumor immune response and enhanced tumor phagocytosis, significantly suppressing tumor growth while prolonging animal survival. Our findings establish a platform technology for directing monocyte differentiation toward anti‐tumor phenotypes, offering a broadly applicable strategy for glioma treatment.
- 5 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (59) , e76910
Open AccessRedirecting Monocyte Differentiation With Engineered Extracellular Vesicles for Glioma Immunotherapy
During glioma progression, monocytes abundantly infiltrate but primarily differentiate into immunosuppressive macrophages to promote tumor growth. Redirecting monocyte differentiation offers a compelling yet underexplored therapeutic opportunity. In this work, we found M1‐polarized macrophage‐derived extracellular vesicles (M1‐EVs) efficiently induced monocytes to differentiate into anti‐tumor macrophages via tumor necrosis factor alpha (TNF‐α)‐mediated signaling. Despite promising, the therapeutic efficacy of M1‐EVs was constrained by insufficient glioma accumulation and CD47‐mediated phagocytic inhibition. To address this challenge, we further engineered M1‐EVs with dual‐targeting specificity by genetically incorporating a tumor‐directed chimeric antigen receptor (CAR) against IL13Rα2 or EGFRvIII together with CD47‐blocking SIRPα variants. The resulting dual‐targeting EVs (M1‐CS‐EVs) exhibited enhanced blood‐brain barrier (BBB) penetration and glioma accumulation while locally disrupting CD47‐SIRPα interactions. In three orthotopic glioma models, M1‐CS‐EVs elicited a potent anti‐tumor immune response and enhanced tumor phagocytosis, significantly suppressing tumor growth while prolonging animal survival. Our findings establish a platform technology for directing monocyte differentiation toward anti‐tumor phenotypes, offering a broadly applicable strategy for glioma treatment.
- Open Access
- 13 January 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Multimodal-based analysis of single-cell ATAC-seq data enables highly accurate delineation of clinically relevant tumor cell subpopulations
Accurately identifying functionally distinct tumor cell subpopulations remains a critical challenge in cancer research. While single-cell epigenomics assay
- 13 January 2026
- Published by Springer Nature in Genome Medicine
- Vol. 18 (1)
Open AccessMultimodal-based analysis of single-cell ATAC-seq data enables highly accurate delineation of clinically relevant tumor cell subpopulations
Accurately identifying functionally distinct tumor cell subpopulations remains a critical challenge in cancer research. While single-cell epigenomics assay
- Open Access
- 19 November 2025
- Published by Shenzhen Medical Academy of Research and Translation
Alternative tandem transcription initiation links noncoding variants to human disease through translational control
Alternative tandem transcription initiation (ATI) is a pervasive mechanism of gene regulation, yet its genetic impact on human disease remains largely unknown. Here, we systematically quantified genetic regulation of ATI across 25,859 samples from 49 human normal tissues and 33 tumor tissues. We identified ~0.4 million 5′ UTR ATI quantitative trait loci (5′aQTLs) in 5,295 genes, with 32% operating independently of gene expression. Moreover, we discovered 2,238 multi-tissue ATI outliers enriched for rare deleterious promoter and 5′ UTR variants, demonstrating that both common and rare variants modulate transcription initiation. Strikingly, 74% of disease variants that colocalize with 5′aQTLs cannot be identified by eQTLs. Transcriptome-wide association studies identified 614 ATI-mediated disease susceptibility genes, including known cancer drivers such as MAFF and MLLT10. Functional validation uncovered OSGEP as a novel breast cancer risk gene, where the alternative allele lengthens the 5′ UTR and reduces protein abundance through upstream open reading frame (uORF)-mediated translation repression, and suppresses breast cancer cell proliferation. Our findings establish ATI as a major, underappreciated mechanism linking noncoding variation to disease, providing a critical resource for interpreting disease risk loci.
- 19 November 2025
- Published by Shenzhen Medical Academy of Research and Translation
Open AccessAlternative tandem transcription initiation links noncoding variants to human disease through translational control
Alternative tandem transcription initiation (ATI) is a pervasive mechanism of gene regulation, yet its genetic impact on human disease remains largely unknown. Here, we systematically quantified genetic regulation of ATI across 25,859 samples from 49 human normal tissues and 33 tumor tissues. We identified ~0.4 million 5′ UTR ATI quantitative trait loci (5′aQTLs) in 5,295 genes, with 32% operating independently of gene expression. Moreover, we discovered 2,238 multi-tissue ATI outliers enriched for rare deleterious promoter and 5′ UTR variants, demonstrating that both common and rare variants modulate transcription initiation. Strikingly, 74% of disease variants that colocalize with 5′aQTLs cannot be identified by eQTLs. Transcriptome-wide association studies identified 614 ATI-mediated disease susceptibility genes, including known cancer drivers such as MAFF and MLLT10. Functional validation uncovered OSGEP as a novel breast cancer risk gene, where the alternative allele lengthens the 5′ UTR and reduces protein abundance through upstream open reading frame (uORF)-mediated translation repression, and suppresses breast cancer cell proliferation. Our findings establish ATI as a major, underappreciated mechanism linking noncoding variation to disease, providing a critical resource for interpreting disease risk loci.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8, 0865
3D Genome Engineering: Current Advances and Therapeutic Opportunities in Human Diseases
Dynamic chromatin 3-dimensional (3D) conformation is a key mechanism regulating gene expression and cellular function during development and disease. Elucidating the structure, functional dynamics, and spatiotemporal organization of the 3D genome requires integrating multiple experimental approaches, including chromatin conformation capture techniques, precise genome manipulation tools, and advanced imaging technologies. Notably, CRISPR/Cas systems have emerged as a revolutionary genome-editing platform, offering unprecedented opportunities for manipulating 3D genome organization and investigating disease mechanisms. This review systematically examines recent advances in CRISPR-based mammalian 3D genome engineering and explores the therapeutic potential of 3D genome engineering strategies in disease intervention.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8, 0865
3D Genome Engineering: Current Advances and Therapeutic Opportunities in Human Diseases
Dynamic chromatin 3-dimensional (3D) conformation is a key mechanism regulating gene expression and cellular function during development and disease. Elucidating the structure, functional dynamics, and spatiotemporal organization of the 3D genome requires integrating multiple experimental approaches, including chromatin conformation capture techniques, precise genome manipulation tools, and advanced imaging technologies. Notably, CRISPR/Cas systems have emerged as a revolutionary genome-editing platform, offering unprecedented opportunities for manipulating 3D genome organization and investigating disease mechanisms. This review systematically examines recent advances in CRISPR-based mammalian 3D genome engineering and explores the therapeutic potential of 3D genome engineering strategies in disease intervention.
- 13 November 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (12) , 2776-2789
JAK/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination
Unipotent basal and luminal stem cells maintain prostate homeostasis, with an intermediate cell population emerging during prostate inflammation or cancer. However, the identities of basal stem cell and intermediate cell population remain unclear. Here we identified a rare intermediate cell population expressing luminal markers (termed Basal-B) with enhanced organoid formation capacity, and a larger basal population (termed Basal-A). Genetic lineage tracing revealed Basal-B cells represented a transient basal stem cell state during prostate homeostasis and androgen-mediated regeneration. Activated JAK/STAT signaling was identified in Basal-B cells, and its inhibition significantly reduced Basal-B markers expression. Inflammation increased Basal-B-to-luminal cell transdifferentiation, but JAK/STAT inhibition notably attenuated this effect. Pten gene deletion increased Nkx3.1-expressing Basal-B-like cell population and led to neoplasia. In humans, h-Basal-B cells were more prevalent in benign prostate hyperplasia. This study reveals the identities of intermediate Basal-B cells and underscores the role of JAK/STAT signaling in prostate cell fate determination.
- 13 November 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (12) , 2776-2789
JAK/STAT signaling maintains an intermediate cell population during prostate basal cell fate determination
Unipotent basal and luminal stem cells maintain prostate homeostasis, with an intermediate cell population emerging during prostate inflammation or cancer. However, the identities of basal stem cell and intermediate cell population remain unclear. Here we identified a rare intermediate cell population expressing luminal markers (termed Basal-B) with enhanced organoid formation capacity, and a larger basal population (termed Basal-A). Genetic lineage tracing revealed Basal-B cells represented a transient basal stem cell state during prostate homeostasis and androgen-mediated regeneration. Activated JAK/STAT signaling was identified in Basal-B cells, and its inhibition significantly reduced Basal-B markers expression. Inflammation increased Basal-B-to-luminal cell transdifferentiation, but JAK/STAT inhibition notably attenuated this effect. Pten gene deletion increased Nkx3.1-expressing Basal-B-like cell population and led to neoplasia. In humans, h-Basal-B cells were more prevalent in benign prostate hyperplasia. This study reveals the identities of intermediate Basal-B cells and underscores the role of JAK/STAT signaling in prostate cell fate determination.
- Open Access
Multimodal integration of single cell ATAC-seq data enables highly accurate delineation of clinically relevant tumor cell subpopulations
Accurately deciphering tumor cellular heterogeneity is crucial for developing effective treatments. While single-cell epigenomics assays offer powerful insights into studying tumor heterogeneity beyond the transcriptional level, their application remains a significant challenge. To address this, we introduce Multimodal-based Analysis of scATAC-Seq data (MAAS), a method designed to identify functional tumor cell subpopulations and reconstruct their lineages from single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq). MAAS uniquely integrates multimodal information, encompassing chromatin accessibility, copy number variations (CNVs), and single-nucleotide variants, through self-expressive multimodal matrix factorization. MAAS outperforms existing methods in accuracy and robustness on both simulated and real datasets. When applied to multiple glioma scATAC-seq datasets, MAAS uncovered a previously hidden tumor cell subpopulation resistant to temozolomide treatment. Furthermore, MAAS effectively detected clinically relevant subpopulations with low CNVs, such as those found in pediatric ependymoma and B-cell lymphoma. Additionally, we developed a novel MAAS-derived clinical signature that provides superior prognostic prediction than traditional clinicopathologic features across multiple cancer types. In summary, MAAS significantly advances the identification of clinically relevant tumor cell subpopulations, thereby accelerating the discovery of potential therapeutic targets.
Open AccessMultimodal integration of single cell ATAC-seq data enables highly accurate delineation of clinically relevant tumor cell subpopulations
Accurately deciphering tumor cellular heterogeneity is crucial for developing effective treatments. While single-cell epigenomics assays offer powerful insights into studying tumor heterogeneity beyond the transcriptional level, their application remains a significant challenge. To address this, we introduce Multimodal-based Analysis of scATAC-Seq data (MAAS), a method designed to identify functional tumor cell subpopulations and reconstruct their lineages from single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq). MAAS uniquely integrates multimodal information, encompassing chromatin accessibility, copy number variations (CNVs), and single-nucleotide variants, through self-expressive multimodal matrix factorization. MAAS outperforms existing methods in accuracy and robustness on both simulated and real datasets. When applied to multiple glioma scATAC-seq datasets, MAAS uncovered a previously hidden tumor cell subpopulation resistant to temozolomide treatment. Furthermore, MAAS effectively detected clinically relevant subpopulations with low CNVs, such as those found in pediatric ependymoma and B-cell lymphoma. Additionally, we developed a novel MAAS-derived clinical signature that provides superior prognostic prediction than traditional clinicopathologic features across multiple cancer types. In summary, MAAS significantly advances the identification of clinically relevant tumor cell subpopulations, thereby accelerating the discovery of potential therapeutic targets.
- Open Access
- 18 June 2024
- Published by Springer Nature in Nature
- Vol. 631 (8019) , E6
Publisher Correction: Sex differences orchestrated by androgens at single-cell resolution
- 18 June 2024
- Published by Springer Nature in Nature
- Vol. 631 (8019) , E6
Open AccessPublisher Correction: Sex differences orchestrated by androgens at single-cell resolution
- Top Cited Papers
- 10 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8010) , 193-200
Sex differences orchestrated by androgens at single-cell resolution
Sex differences in mammalian complex traits are prevalent and are intimately associated with androgens1,2,3,4,5,6,7. However, a molecular and cellular profile of sex differences and their modulation by androgens is still lacking. Here we constructed a high-dimensional single-cell transcriptomic atlas comprising over 2.3 million cells from 17 tissues in Mus musculus and explored the effects of sex and androgens on the molecular programs and cellular populations. In particular, we found that sex-biased immune gene expression and immune cell populations, such as group 2 innate lymphoid cells, were modulated by androgens. Integration with the UK Biobank dataset revealed potential cellular targets and risk gene enrichment in antigen presentation for sex-biased diseases. This study lays the groundwork for understanding the sex differences orchestrated by androgens and provides important evidence for targeting the androgen pathway as a broad therapeutic strategy for sex-biased diseases.
- 10 April 2024
- Published by Springer Nature in Nature
- Vol. 629 (8010) , 193-200
Top Cited PapersSex differences orchestrated by androgens at single-cell resolution
Sex differences in mammalian complex traits are prevalent and are intimately associated with androgens1,2,3,4,5,6,7. However, a molecular and cellular profile of sex differences and their modulation by androgens is still lacking. Here we constructed a high-dimensional single-cell transcriptomic atlas comprising over 2.3 million cells from 17 tissues in Mus musculus and explored the effects of sex and androgens on the molecular programs and cellular populations. In particular, we found that sex-biased immune gene expression and immune cell populations, such as group 2 innate lymphoid cells, were modulated by androgens. Integration with the UK Biobank dataset revealed potential cellular targets and risk gene enrichment in antigen presentation for sex-biased diseases. This study lays the groundwork for understanding the sex differences orchestrated by androgens and provides important evidence for targeting the androgen pathway as a broad therapeutic strategy for sex-biased diseases.
- Open Access
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in BME Frontiers
- Vol. 5, 0047
Engineering Bacteria and Their Derivatives for Cancer Immunotherapy
Leveraging bacteria for cancer immunotherapy has gradually attracted wide attention since the discovery of “Cloey’s toxin.” However, one of the persistent challenges for bacteria-based therapy is striking a balance between safety and immunogenicity. Genetically engineered bacteria with virulence factors removed could further enhance antitumor ability by integrating genetic elements. In addition, bacterial derivatives, including outer membrane vesicles (OMVs) produced by bacterial secretion and nanovesicles synthesized by modification of OMVs, could enhance antitumor immunity while improving safety. This perspective discusses the unique advantages of engineered bacteria and their derivatives for immunotherapy, as well as the challenges that need to be overcome to achieve clinical translation.
- 1 January 2024
- Published by American Association for the Advancement of Science (AAAS) in BME Frontiers
- Vol. 5, 0047
Open AccessEngineering Bacteria and Their Derivatives for Cancer Immunotherapy
Leveraging bacteria for cancer immunotherapy has gradually attracted wide attention since the discovery of “Cloey’s toxin.” However, one of the persistent challenges for bacteria-based therapy is striking a balance between safety and immunogenicity. Genetically engineered bacteria with virulence factors removed could further enhance antitumor ability by integrating genetic elements. In addition, bacterial derivatives, including outer membrane vesicles (OMVs) produced by bacterial secretion and nanovesicles synthesized by modification of OMVs, could enhance antitumor immunity while improving safety. This perspective discusses the unique advantages of engineered bacteria and their derivatives for immunotherapy, as well as the challenges that need to be overcome to achieve clinical translation.